SCHEMBL23453756

SCHEMBL23453756

Cc1snc(C(=O)O)c1Nc1ccc(-c2ccc(C#N)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 1/20 0.40
▸ VCP P55072 1/20 0.40
▸ GSK3A P49840 1/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ DHODH Q02127 1/20 0.39
▸ ABCG2 Q9UNQ0 2/20 0.38
▸ KCNH2 Q12809 1/20 0.37
▸ SCN10A Q9Y5Y9 1/20 0.37
▸ MAPKAPK2 P49137 1/20 0.37
▸ PTGER4 P35408 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ CREBBP Q92793 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ ABCB1 P08183 1/20 0.36
▸ SIRT5 Q9NXA8 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22609280 0.96 GSK3A (0.42) CSF1RVCPGSK3AGSK3BDHODH
SCHEMBL23453734 0.89 SYK (0.43) CSF1RGSK3AABCG2KCNH2SCN10A
SCHEMBL23453725 0.85 KDM4E (0.43) GSK3AGSK3BDHODHALDH1A1KDM4E
SCHEMBL22609261 0.81 KDM4E (0.46) GSK3AGSK3BDHODHALDH1A1KDM4E
SCHEMBL22609217 0.79 KDM1A (0.43) DHODHKDM4ENPSR1SMN1; SMN2
SCHEMBL23453717 0.78 DHODH (0.41) CSF1RGSK3BDHODHABCG2KCNH2
SCHEMBL23453707 0.78 DHODH (0.53) CSF1RDHODH
SCHEMBL22609308 0.75 FABP5 (0.43) GSK3AGSK3BPTGER4KDM4E
SCHEMBL23486308 0.74 VCP (0.37) CSF1RVCPGSK3BDHODHABCG2
SCHEMBL23453746 0.73 DHODH (0.53) DHODHALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS CSF1R 1887/4885VCP 3734/4885GSK3A 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback